2023
Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation
Bhagchandani S, Vohidov F, Milling L, Tong E, Brown C, Ramseier M, Liu B, Fessenden T, Nguyen H, Kiel G, Won L, Langer R, Spranger S, Shalek A, Irvine D, Johnson J. Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. Science Advances 2023, 9: eadg2239. PMID: 37075115, PMCID: PMC10115420, DOI: 10.1126/sciadv.adg2239.Peer-Reviewed Original ResearchConceptsToll-like receptor 7Cancer immunotherapyImmune stimulationMouse syngeneic tumor modelsNext-generation cancer immunotherapyImmune-related toxicitiesAcute systemic inflammationInnate immune cellsSyngeneic tumor modelsPotential cancer immunotherapySystemic inflammationImmune cellsReceptor 7Systemic administrationIntravenous administrationMyeloid cellsTumor growthSystemic toxicityTumor modelObservable systemic toxicityPotent stimulationImidazoquinolinesImmunotherapyStimulationProdrugMolecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma
Detappe A, Nguyen H, Jiang Y, Agius M, Wang W, Mathieu C, Su N, Kristufek S, Lundberg D, Bhagchandani S, Ghobrial I, Ghoroghchian P, Johnson J. Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma. Nature Nanotechnology 2023, 18: 184-192. PMID: 36702954, PMCID: PMC10032145, DOI: 10.1038/s41565-022-01310-1.Peer-Reviewed Original ResearchConceptsCombination therapyMultiple myelomaNarrow therapeutic indexMultiple myeloma therapyFree drug combinationFree drug counterpartsMyeloma therapySame doseTherapeutic indexTumor progressionBPD exhibitTherapyProteasome inhibitorsCombination nanomedicinesCancer therapyMonotherapyMyelomaSynergistic ratio
2016
A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer
Levy O, Brennen W, Han E, Rosen D, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani S, Joshi N, Bhowmick N, Denmeade S, Isaacs J, Karp J. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials 2016, 91: 140-150. PMID: 27019026, PMCID: PMC4824400, DOI: 10.1016/j.biomaterials.2016.03.023.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsCell Line, TumorCells, CulturedDrug Delivery SystemsHumansLactic AcidMaleMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMice, NudePolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerProdrugsProstateProstate-Specific AntigenProstatic NeoplasmsConceptsMesenchymal stem cellsDelivery platformDrug delivery platformSystemic delivery platformHuman mesenchymal stem cellsCell-based deliveryGenetic engineeringProstate cancerDisseminated prostate cancerPCa cell linesProstate-specific antigenProstate cancer researchLoaded cellsMicroparticlesStem cellsPromising approachPCa xenograftsMetastatic PCaPlatformCancer sitesAnti-cancer drugsPotential treatmentSpecific antigenCancer growthTumor growth